Skip to main content
SpringerLink
Log in

Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?

  • IM - COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2018) Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 137(12):e67–e492

    Article  PubMed  Google Scholar 

  2. Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L, Crijns HJ, Tavazzi L, Maggioni AP, Lip GY (2016) Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep 6:30271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367(7):625–635

    Article  CAS  PubMed  Google Scholar 

  4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962

    Article  Google Scholar 

  5. Riva N, Ageno W (2015) Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 41(2):178–187

    Article  CAS  PubMed  Google Scholar 

  6. Malavasi VL, Pettorelli D, Fantecchi E, Zoccali C, Laronga G, Trenti T, Lip GYH, Boriani G (2018) Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function—post-hoc analysis of a prospective cohort. Intern Emerg Med. https://doi.org/10.1007/s11739-018-1857-3

    Article  Google Scholar 

  7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150

    Article  Google Scholar 

  8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators ROCKETAF (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891

    Article  CAS  PubMed  Google Scholar 

  9. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104

    Article  CAS  PubMed  Google Scholar 

  10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    Article  CAS  PubMed  Google Scholar 

  11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992

    Article  CAS  PubMed  Google Scholar 

  12. Sciascia S, Radin M, Schreiber K, Fenoglio R, Baldovino S, Roccatello D (2017) Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med 12(8):1101–1108

    Article  PubMed  Google Scholar 

  13. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393

    Article  PubMed  Google Scholar 

  14. Dowling TC, Wang ES, Ferrucci L, Sorkin JD (2013) Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. Pharmacotherapy 33(9):912–921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cirillo M, Anastasio P, De Santo NG (2005) Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 20(9):1791–1798

    Article  PubMed  Google Scholar 

  16. Becattini C, Giustozzi M, Ranalli MG, Bogliari G, Cianella F, Verso M, Agnelli G, Vedovati MC (2018) Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. J Thromb Haemost 16(5):833–841

    Article  CAS  PubMed  Google Scholar 

  17. Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine), FADOI (Federation of Associations of Hospital Doctors on Internal Medicine), SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387–406

    Article  PubMed  Google Scholar 

  18. Minhas AS, Jiang Q, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD (2016) Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. J Thromb Thrombolysis 42(4):566–572

    Article  CAS  PubMed  Google Scholar 

  19. Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ, Packer DL, Noseworthy PA (2016) Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol 117(1):69–75

    Article  CAS  PubMed  Google Scholar 

  20. European Medicines Agency. Eliquis (apixaban): summary of product characteristics. http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_Product_Information/human/002148/WC500107728pdf. Accessed 8 Apr 2018

  21. European Medicines Agency. Pradaxa (dabigatran etexilate): summary of product characteristics. http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_Product_Information/human/000829/WC500041059pdf. Accessed 8 Apr 2018

  22. European Medicines Agency. Lixiana (edoxaban): summary of product characteristics. http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_Product_Information/human/002629/WC500189045pdf. Accessed 8 Apr 2018

  23. European Medicines Agency. Xarelto (rivaroxaban): summary of product characteristics. http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_Product_Information/human/000944/WC500057108pdf. Accessed 8 Apr 2018

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

    Nicoletta Riva & Alex Gatt

  2. Department of Medicine and Surgery, University of Insubria, Varese, Italy

    Walter Ageno

Authors
  1. Nicoletta Riva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter Ageno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alex Gatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicoletta Riva.

Ethics declarations

Conflict of interest

The Authors declare that they  have no conflict of interest.

Statement of human and animal rights

Not applicable.

Informed consent

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riva, N., Ageno, W. & Gatt, A. Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?. Intern Emerg Med 13, 1001–1004 (2018). https://doi.org/10.1007/s11739-018-1883-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-018-1883-1

Keywords

Search

Navigation